drugset

drugset / Trial / NCT00318669

Social Anxiety Disorder Study Of Paroxetine

NCT00318669 ↗

Phase 3 Completed 390 enrolled GlaxoSmithKline

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety in Social Anxiety Disorder (SAD).

Timeline

Start: 2005-12
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paroxetine	Small molecule	—	—

Indications